Targeting BCMA in Multiple Myeloma: Evidence-Based Guidance for Current and Near-Future Clinical Integration

Read this module from Nina Shah, MD, to learn more about how BCMA-targeted agents work in multiple myeloma and how you can use these agents in clinical practice to improve patient outcomes.

Nina Shah, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: April 4, 2022 Expired: No longer available for credit

Download these slides with the most recent data on BCMA-targeted agents in multiple myeloma, including information on mechanism of action, clinical trial data, and implications for clinical practice.

Learn how experts incorporate BCMA-directed therapies for multiple myeloma into their practice.

Nina Shah, MD Released: February 2, 2022

We’ve heard a great deal about BCMA-targeted CAR T-cell therapy and antibody–drug conjugates for R/R MM. In this commentary, Dr Sagar Lonial discusses how BCMA-targeted bispecific therapies will fit in to the treatment landscape.

Sagar Lonial, MD Released: April 14, 2022

Download this resource developed to serve as a helpful guide for healthcare professionals on the use of BCMA-targeted therapies for treatment of multiple myeloma.